[13] In combination with a reduced-calorie diet and increased physical activity, semaglutide (as Wegovy) is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and who are either obese or overweight
Direct answer: A 503A pharmacy compounds medicine for a specific patient when a licensed prescriber determines a medical need
Zepbound activates both GIP and GLP-1 receptors, meaning it has a dual mechanism of action, compared to semaglutide and orforglipron, which only activate GLP-1 receptors
When to Seek Medical Attention Certain symptoms require immediate medical evaluation
If you experience any adverse effects following the use of a reconstituted peptide preparation including injection-site reactions, nausea, hypoglycaemia, or signs of infection contact your GP promptly
trial participants must report adverse events directly to their trial team
